The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 09, 2019

Filed:

Feb. 27, 2015
Applicant:

Astellas Pharma Inc., Chuo-ku, Tokyo, JP;

Inventors:

Satoshi Takeuchi, Tokyo, JP;

Masahito Sato, Tokyo, JP;

Jotarou Suzuki, Tokyo, JP;

Shinji Soga, Tokyo, JP;

Jun Takasaki, Tokyo, JP;

Koji Aoyama, Tokyo, JP;

Chie Okuyama, Tokyo, JP;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C12N 15/63 (2006.01); C12N 15/64 (2006.01); C12N 5/12 (2006.01); C07K 14/705 (2006.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2896 (2013.01); C12N 5/12 (2013.01); C12N 15/63 (2013.01); C07K 16/28 (2013.01); C07K 2317/31 (2013.01); C07K 2317/40 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01); C12N 15/64 (2013.01);
Abstract

The present application provides a bispecific antibody for preventing or treating an immune inflammatory disease by acting on both human TLR2 and human TLR4 to inhibit human TLR2- and human TLR4-mediated immune inflammatory effects. More specifically, the provided bispecific antibody is a bispecific antibody for human TLR2 and human TLR4, including a heavy chain variable region of an anti-human TLR2 antibody consisting of the amino acid sequence of amino acid numbers 1 to 120 of SEQ ID NO: 4; a light chain variable region of an anti-human TLR2 antibody consisting of the amino acid sequence of amino acid numbers 1 to 113 of SEQ ID NO: 6; a heavy chain variable region of an anti-human TLR4 antibody consisting of the amino acid sequence of amino acid numbers 491 to 609 of SEQ ID NO: 4; and a light chain variable region of an anti-human TLR4 antibody consisting of the amino acid sequence of amino acid numbers 625 to 732 of SEQ ID NO: 4.


Find Patent Forward Citations

Loading…